{"title":"高龄高危mds转化型急性髓系白血病症状管理成功病例报告","authors":"Hakobyan Y","doi":"10.23880/hij-16000191","DOIUrl":null,"url":null,"abstract":"American Society of Hematology (ASH) recommends antileukemic therapy over best supportive care for older adults with acute myeloid leukemia (AML) [1]. According to the SEER database from 2010 to 2017, the 5-year overall survival (OS) in individuals with AML diagnosis over 70 years of age was around 5% [2]. We describe a case of nearly one-year survival in an elderly patient with a very high-risk myelodysplastic syndrome (MDS) that later transformed into AML with supportive therapy only.","PeriodicalId":245976,"journal":{"name":"Haematology International Journal","volume":"76 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report of Successful Symptomatic Management of Elderly Patient with Very High-Risk MDS-Transformed AML\",\"authors\":\"Hakobyan Y\",\"doi\":\"10.23880/hij-16000191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"American Society of Hematology (ASH) recommends antileukemic therapy over best supportive care for older adults with acute myeloid leukemia (AML) [1]. According to the SEER database from 2010 to 2017, the 5-year overall survival (OS) in individuals with AML diagnosis over 70 years of age was around 5% [2]. We describe a case of nearly one-year survival in an elderly patient with a very high-risk myelodysplastic syndrome (MDS) that later transformed into AML with supportive therapy only.\",\"PeriodicalId\":245976,\"journal\":{\"name\":\"Haematology International Journal\",\"volume\":\"76 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23880/hij-16000191\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23880/hij-16000191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Case Report of Successful Symptomatic Management of Elderly Patient with Very High-Risk MDS-Transformed AML
American Society of Hematology (ASH) recommends antileukemic therapy over best supportive care for older adults with acute myeloid leukemia (AML) [1]. According to the SEER database from 2010 to 2017, the 5-year overall survival (OS) in individuals with AML diagnosis over 70 years of age was around 5% [2]. We describe a case of nearly one-year survival in an elderly patient with a very high-risk myelodysplastic syndrome (MDS) that later transformed into AML with supportive therapy only.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
